Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice

INTRODUCTION: Oncogenic driver mutations activating EGFR, ALK, or BRAF in NSCLC predict sensitivity to specific tyrosine-kinase inhibitors (TKIs). We provide data on prevalence, treatment and survival of driver-mutation positive NSCLC in a predominantly Caucasian population in routine clinical pract...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Faehling, Martin, Schwenk, Birgit, Kramberg, Sebastian, Eckert, Robert, Volckmar, Anna-Lena, Stenzinger, Albrecht, Sträter, Jörn
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2017
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652823/
https://ncbi.nlm.nih.gov/pubmed/29100434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20857
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items